Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 14/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25947633 | 0.76 | PIN1 (0.46) | PIN1HPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL28984664 | 0.75 | HPGD (0.61) | PIN1HPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL30635855 | 0.75 | PIN1 (0.64) | PIN1ALDH1A1HTTGAAEGFR | |
| SCHEMBL30378947 | 0.75 | LCK (0.46) | PIN1ALDH1A1HTTGAA | |
| SCHEMBL3334570 | 0.75 | PIN1 (0.64) | PIN1ALDH1A1HTTGAAEGFR | |
| SCHEMBL26087125 | 0.75 | LCK (0.46) | PIN1ALDH1A1HTTGAA | |
| SCHEMBL1707043 | 0.74 | PIN1 (0.58) | PIN1HTTEGFR | |
| SCHEMBL12620328 | 0.74 | PIN1 (1.00) | PIN1 | |
| SCHEMBL30584631 | 0.74 | PIN1 (0.60) | PIN1HPGDALDH1A1HTTGAA | |
| SCHEMBL30584582 | 0.74 | PIN1 (0.56) | PIN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745127-A1 | PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Technoderma Medicines Inc. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-116947764-B | Pyrimidamine NUAK inhibitor and preparation method and application thereof | 特科罗生物科技(成都)有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025011444-A1 | PYRIMIDINAMINE NUAK INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 特科罗生物科技(成都)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-116947764-A | Pyrimidine amine NUAK inhibitor and preparation method and application thereof | 特科罗生物科技(成都)有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2099771-A1 | PYRIMIDINE KINASE INHIBITORS | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079719-A1 | PYRIMIDINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144732-A1 | PYRIMIDINE KINASE INHIBITORS | DTYMK, DCK, TYMP | PIN1 2781/4885HPGD 2984/4885ALDH1A1 3289/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | PIN1 656/4885HPGD 1632/4885ALDH1A1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.